FINDING THE OPTIMAL TREATMENT STRATEGY FOR DISEASE ACTIVITY-GUIDED DOSE REDUCTION OF ADALIMUMAB AND ETANERCEPT IN RHEUMATOID ARTHRITIS: A MODELLING STUDY

被引：0
|
作者：
Verhoef, L. M. [1 ]
Bos, D. P. [1 ]
van den Ende, C. H. [1 ,2 ]
van den Hoogen, F. H. [1 ,2 ]
Fautrel, B. [3 ]
Hulscher, M. E. [4 ]
Kievit, W. [5 ]
den Broeder, A. A. [1 ,2 ]
机构：
[1] St Maartenskliniek, Rheumatol, Nijmegen, Netherlands
[2] Radboudumc, Rheumatol, Nijmegen, Netherlands
[3] Hop La Pitie Salpetriere, Rheumatol, Paris, France
[4] RIHS, IQ Healthcare, Nijmegen, Netherlands
[5] Radboudumc, RIHS, Hlth Evidence, Nijmegen, Netherlands
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2018年 / 77卷
关键词：
D O I：
10.1136/annrheumdis-2018-eular.2604
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
THU0207
引用
收藏
页码：323 / 323
页数：1
相关论文
共 50 条
  • [41] Increased disease activity in rheumatoid arthritis patients before and during one year of treatment with etanercept.
    Yazici, Y
    Belostocki, KB
    Erkan, D
    Mashenskaya, L
    Harrison, MJ
    ARTHRITIS AND RHEUMATISM, 2000, 43 (09): : S229 - S229
  • [42] Clinical response to golimumab in rheumatoid arthritis patients who were receiving etanercept or adalimumab: results of a multicenter active treatment study
    Huffstutter, Joseph E.
    Kafka, Shelly
    Brent, Lawrence H.
    Matucci-Cerinic, Marco
    Tang, Kezhen L.
    Chevrier, Marc
    Sprabery, Trev
    DeHoratius, Raphael J.
    CURRENT MEDICAL RESEARCH AND OPINION, 2017, 33 (04) : 657 - 666
  • [43] Optimal responses in disease activity scores to treatment in rheumatoid arthritis: Is a DAS28 reduction of >1.2 sufficient?
    Mian, Aneela N.
    Ibrahim, Fowzia
    Scott, David L.
    Galloway, James
    ARTHRITIS RESEARCH & THERAPY, 2016, 18
  • [44] Towards optimal cut-off trough levels of adalimumab and etanercept for a good therapeutic response in rheumatoid arthritis. Results of the INMUNOREMAR study
    Sanmarti, Raimon
    Inciarte-Mundo, Jose
    Estrada-Alarcon, Paula
    Garcia-Manrique, Maria
    Narvaez, Javier
    Rodriguez-Moreno, Jesus
    Gomez-Centeno, Antoni
    Pascal, Mariona
    Yaguee, Jordi
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 (08)
  • [45] A multi-biomarker score measuring disease activity in rheumatoid arthritis patients tapering adalimumab or etanercept: predictive value for clinical and radiographic outcomes
    Bouman, Chantal A. M.
    van der Maas, Aatke
    van Herwaarden, Noortje
    Sasso, Eric H.
    van den Hoogen, Frank H. J.
    den Broeder, Alfons A.
    RHEUMATOLOGY, 2017, 56 (06) : 973 - 980
  • [46] Disease Activity States Following One Year of Etanercept Treatment: Outcomes in Moderate vs Severe Rheumatoid Arthritis
    Keystone, Edward
    Freundlich, Bruce
    Schiff, Michael
    Li, Juan
    Hooper, Michele
    JOURNAL OF RHEUMATOLOGY, 2009, 36 (11) : 2577 - 2577
  • [47] Dose reduction of rituximab in clinical practice: a retrospective cohort study of rheumatoid arthritis patients in low disease activity on rituximab
    Wientjes, M. H. M.
    van Huissteden, J.
    van Herwaarden, N.
    Verhoef, L. M.
    den Broeder, A. A.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2024, 42 (11) : 2215 - 2220
  • [48] Is There an Optimal Treatment Strategy for Disease-Modifying-Antirheumatic-Drug Naive Patients with Rheumatoid Arthritis?
    Akkineni, Roopa
    Albert, Daniel A.
    ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S403 - S403
  • [49] Treatment strategy, disease activity, and outcome in four cohorts of patients with early rheumatoid arthritis
    Albers, JMC
    Paimela, L
    Kurki, P
    Eberhardt, KB
    Emery, P
    van't Hof, MA
    Schreuder, FHJM
    Leirisalo-Repo, M
    van Riel, PLCM
    ANNALS OF THE RHEUMATIC DISEASES, 2001, 60 (05) : 453 - 458
  • [50] A Multi-Biomarker Disease Activity (VECTRA™ DA Algorithm) Score Reflects Clinical Disease Activity and Tracks Responses in Patients with Rheumatoid Arthritis Treated with Either Adalimumab, Etanercept, and Infliximab
    Hirata, Shintaro
    Haney, Douglas J.
    Cavet, Guy
    Bolce, Rebecca
    Li, Wanying
    Defranoux, Nadine
    Chernoff, David
    Yamaoka, Kunihiro
    Saito, Kazuyoshi
    Tanaka, Yoshiya
    ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S1130 - S1130
12345